Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. Show more

Location: 60 First Street, Cambridge, MA, 02141, United States | Website: https://primemedicine.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

324.3M

52 Wk Range

$1.11 - $6.75

Previous Close

$2.47

Open

$2.43

Volume

3,643,500

Day Range

$2.28 - $2.78

Enterprise Value

292.6M

Cash

144.3M

Avg Qtr Burn

-26.0M

Insider Ownership

24.22%

Institutional Own.

56.84%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.